ArticleCurrent oncology (Toronto, Ont.)2026

Efficacy of Lenvatinib as Second-Line Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.

Daichi Takizawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.